Correction: miR-874 functions as a tumor suppressor by inhibiting angiogenesis through STAT3/VEGF-A pathway in gastric cancer

Xiaoyu Zhang; Jie Tang; Xiaofei Zhi; Kunling Xie; Weizhi Wang; Zheng Li; Yi Zhu; Li Yang; Hao Xu; Zekuan Xu

doi:10.18632/oncotarget.17402

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: miR-874 functions as a tumor suppressor by inhibiting angiogenesis through STAT3/VEGF-A pathway in gastric cancer

Xiaoyu Zhang, Jie Tang, Xiaofei Zhi, Kunling Xie, Weizhi Wang, Zheng Li, Yi Zhu, Li Yang, Hao Xu and Zekuan Xu _

PDF | How to cite

Oncotarget. 2017; 8:29535-29535. https://doi.org/10.18632/oncotarget.17402

Metrics: PDF 3089 views | ?

Present: The Acknowledgement information is incomplete.

Correct: The proper funding acknowledgements are given below.

ACKNOWLEDGMENTS

This work was supported by the National Natural Science Foundation Project of International Cooperation (NSFC-NIH, 81361120398); the National Natural Science Foundation of China (81272712, 30901421); the Program for Development of Innovative Research Team in the First Affliated Hospital of NJMU; the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD, JX10231801) and the translational research of early diagnosis and comprehensive treatment in pancreatic cancer (The research Special Fund For public welfare industry of health,201202007).

Original article: Oncotarget. 2015; 6:1605-17. DOI: 10.18632/oncotarget.2748.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17402

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: miR-874 functions as a tumor suppressor by inhibiting angiogenesis through STAT3/VEGF-A pathway in gastric cancer